More than a year after the FDA yanked away authorization from Evusheld, a monoclonal antibody treatment for COVID-19, the agency granted emergency use authorization to a new COVID-19 preventive drug March 22.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
